Skip to main content
MANE
NYSE Life Sciences

Veradermics Sets Nov. 9 Call to Unveil 12-Month Phase 3 '302' Hair Loss Data

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$139.33
Mkt Cap
$5.798B
52W Low
$32
52W High
$146.575
52W Position info
335% above low
Off High info
4.9% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Veradermics will host an investor call and webcast Monday, November 9 at 8:00 am ET to review topline 12-month results from Part B of the Phase 3 '302' trial of VDPHL01, its extended-release oral minoxidil, in over 500 men with mild-to-moderate pattern hair loss. The call is the data event itself — the results are not in this release, so direction is unknown until the numbers land. This follows the October 19 disclosure that Phase 3 Study '304' hit both co-primary endpoints with high statistical significance in 536 men, which is the bar the '302' readout will be measured against. VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both men and women if approved, and the company cites a market projected near $30 billion by 2028. Note the stock sits near its 52-week high after a wave of insider selling in August, including a $80.4 million block at $107.25, so positioning is crowded into this print.

At the time of this announcement, MANE was trading at $139.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $32.00 to $146.58. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $108.01
Real-time Price: $139.33 info
Change: +$31.32 (+29%) info
Market Cap: $5.798B info
MANE
Oct 18, 2026, 6:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $108.82
Real-time Price: $139.33 info
Change: +$30.51 (+28%) info
Market Cap: $5.798B info
MANE
Aug 21, 2026, 6:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $102.82
Real-time Price: $139.33 info
Change: +$36.51 (+36%) info
Market Cap: $5.798B info
MANE
Aug 21, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $102.82
Real-time Price: $139.33 info
Change: +$36.51 (+36%) info
Market Cap: $5.798B info
MANE
Aug 17, 2026, 5:30 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.22
Real-time Price: $139.33 info
Change: +$31.11 (+29%) info
Market Cap: $5.798B info